RT Journal Article
SR Electronic
T1 Practical aspects of targeting IL-6 in COVID-19 disease
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
DO 10.3949/ccjm.87a.ccc018
A1 Cassandra Calabrese
A1 Prabalini Rajendram
A1 Gretchen L. Sacha
A1 Leonard Calabrese
YR 2020
UL http://www.ccjm.org/content/early/2020/10/07/ccjm.87a.ccc018.abstract
AB Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of immune-mediated disease states, they have not been used often in the intensive care setting, and new data question their efficacy. This brief review provides practical information on their administration and safety.